Google+ Badge

Wednesday, March 5, 2014

3/4/14 Health News: CONTROLLING SALMONELLA - Cashiers May Absorb Controversial Chemical When Handling Receipts- Pneumonia Vaccine

CONTROLLING SALMONELLA WOULD COST FARMERS
Controlling Salmonella or other pathogens would cost producers, and the cost would be expected to be transferred to processors and consumers. For animal pathogens, the USDA’s APHIS bears some of the burden and indemnifies producers for destroyed flocks. Many producers currently bear the cost of preventing animal pathogens from infecting their flocks and herds through... Continue Reading
Cashiers May Absorb Controversial Chemical When Handling Receipts


People who work a cash register all day are most likely absorbing a potentially toxic chemical from the receipts they handle, new research finds. Thermal receipt paper contains bisphenol A (BPA), which is used to prevent the color on paper from running or bleeding. Researchers discovered that people working a two-hour shift at a cash register saw their BPA levels increase three to five times from handling the receipts. Continue Reading
\
Flu Hit Working-age Adults Hardest This Year


Young people and middle-aged adults were at high risk this flu season. Working-age adults accounted for 61% of influenza hospitalizations, the Centers for Disease Control and Prevention reported. Last flu season, about 35% of flu hospitalizations were in people ages 18 to 64, CDC reported. People in that age range accounted for about 60% of flu deaths. That compared with 18%, 30% and 47% for the three previous seasons, the CDC reported. "One of the reasons flu is hitting young adults hard is such a low proportion, get the flu shot," said CDC Director Tom Frieden. "Only one-third were vaccinated." That's in contrast to a 60% vaccination rate for seniors and more than 50% for children.Continue Reading


Pfizer Pneumonia Vaccine Study Meets Clinical Objectives

Pfizer Inc. said a clinical study of its pneumonia vaccine treatment for older adults showed the immunization prevented several kinds of community-acquired pneumonia. Pfizer's Prevnar 13 is a vaccine meant to prevent pneumococcal diseases, or illnesses caused by s. pneumoniae bacteria, which occur when the bacteria enters the bloodstream or causes an infection in the lungs. The Prevnar 13 trial tested the effectiveness of the vaccine in 85,000 patients aged 65 or older against pneumonia, which Pfizer said makes it the largest double-blind, randomized, placebo-controlled vaccine efficacy trial conducted in adults. The immunization was effective against the first episode of community-acquired pneumonia, or pneumonia spread from normal social contact rather than a hospital. Prevnar 13 also prevented the first episode of non-invasive community-acquired pneumonia as well as the first episode of vaccine-type invasive pneumococcal disease..Continue Reading

No comments:

Post a Comment